About this trial
Fluorescence-guided surgery using indocyanine green can visualize the complex and diverse lymph node drainage structures for each patient and help determine the extent of dissection of the D3 lymph node tailored to the patient. However, since fluorescence lymph node mapping (FLNM) is still being conducted only at some institutions for research purposes and is limited to reporting the results of small-scale studies of patients, a large-scale multi-center study was conducted to verify the clinical-oncological effects of FLNM. Research is needed.
Therefore, this study used real-time fluorescence lymph node mapping (FLNM) to determine the extent of D3 lymph node dissection when performing right hemicolectomy and D3 lymph node dissection in patients with locally advanced right-sided colon cancer and to safely remove extensive lymph nodes. We aim to evaluate whether the dissection procedure is safe and beneficial in terms of clinical oncology.
Eligibility criteria
Qualifiers
Patients who over 19 years old, Under 85 years old
Patient with locally advanced right colon cancer requiring D3 lymphadenectomy
Colon cancer patients diagnosed with clinical stage cT3-4 N0 or cTany N1-2 before surgery
Patient with right-sided colon cancer located in the cecum, ascending colon, flexure colon, and proximal transverse colon.
Disqualifiers
Patients with a history of allergy or side effects to sodium iodine
Patients with colon cancer who have distant or peritoneal metastases
Patients requiring emergency surgery due to colon obstruction or colon perforation
Patients with inflammatory bowel disease not controlled by drug treatment
Trial design
Treatments tested in this trial
- Indocyanine green (ICG) injection for intraoperative lymph node imaging
- Standard Right Hemicolectomy (Non-ICG)